Trung, T.N., Tan, B., Van Phuc, D. et al. A randomized, controlled trial of artemisinin-piperaquine vs dihydroartemisinin-piperaquine phosphate in treatment of falciparum malaria., Chin. J. Integr. Med. 15, 189–192 (2009). https://doi.org/10.1007/s11655-009-0189-6
Trieu Nguyen Trung, Bo Tan, Dang Van Phuc, et al. A randomized, controlled trial of artemisinin-piperaquine vs dihydroartemisinin-piperaquine phosphate in treatment of falciparum malaria[J]. Chinese Journal of Integrative Medicine, 2009,15(3):189-192.
Trung, T.N., Tan, B., Van Phuc, D. et al. A randomized, controlled trial of artemisinin-piperaquine vs dihydroartemisinin-piperaquine phosphate in treatment of falciparum malaria., Chin. J. Integr. Med. 15, 189–192 (2009). https://doi.org/10.1007/s11655-009-0189-6DOI:
Trieu Nguyen Trung, Bo Tan, Dang Van Phuc, et al. A randomized, controlled trial of artemisinin-piperaquine vs dihydroartemisinin-piperaquine phosphate in treatment of falciparum malaria[J]. Chinese Journal of Integrative Medicine, 2009,15(3):189-192. DOI: 10.1007/s11655-009-0189-6.
A randomized, controlled trial of artemisinin-piperaquine vs dihydroartemisinin-piperaquine phosphate in treatment of falciparum malaria
摘要
The study aimed to evaluate and compare the efficacy and safety of dihydroartemisinin-piperaquine phosphate (Artekin) and artemisinin-piperaquine (Artequick) in the treatment of uncomplicated falciparum malaria. A total of 103 uncomplicated falciparum malaria patients were enrolled and randomly assigned to two groups: 52 cases in the Artequick group
and 51 cases in the Artekin group. The patients in the Artequick group were administered with Artequick
twice in 24 h
whereas the patients in the Artekin group were given Artekin 4 times in 2 days. The mean parasite clearance time
mean fever clearance time
28-day cure rate and parasite recrudescence rates of the two groups were then compared. The mean parasite clearance time and the mean fever clearance time were 43.2±13.9 h and 24.7±9.9 h
in the Artequick group
and 36.5±17.1 h and 22.7±11.2 h
in the Artekin group. In both groups the 28-day cure rate was 100%
and the parasite recrudescence rate was 0. Both medicines had high cure rates
low recrudescence rates
and no serious adverse reactions. The administration of Artequick
however
was more convenient and lower incidence of gastrointestinal side effects than that of Artekin
so as to increase the efficacy in the malaria population.
Abstract
The study aimed to evaluate and compare the efficacy and safety of dihydroartemisinin-piperaquine phosphate (Artekin) and artemisinin-piperaquine (Artequick) in the treatment of uncomplicated falciparum malaria. A total of 103 uncomplicated falciparum malaria patients were enrolled and randomly assigned to two groups: 52 cases in the Artequick group
and 51 cases in the Artekin group. The patients in the Artequick group were administered with Artequick
twice in 24 h
whereas the patients in the Artekin group were given Artekin 4 times in 2 days. The mean parasite clearance time
mean fever clearance time
28-day cure rate and parasite recrudescence rates of the two groups were then compared. The mean parasite clearance time and the mean fever clearance time were 43.2±13.9 h and 24.7±9.9 h
in the Artequick group
and 36.5±17.1 h and 22.7±11.2 h
in the Artekin group. In both groups the 28-day cure rate was 100%
and the parasite recrudescence rate was 0. Both medicines had high cure rates
low recrudescence rates
and no serious adverse reactions. The administration of Artequick
however
was more convenient and lower incidence of gastrointestinal side effects than that of Artekin
so as to increase the efficacy in the malaria population.
Jose A. Najera, Joahim Hempel. The burden of malaria, CTD/MAL/96.10. http://www.rbm.who.int/cmc_upload/0/000/009/511/burden_najera.pdf
WHO. World malaria report. Geneva: World Health Organization; 2005. http://www.unicef.org/media/files/MalariaFactSheet.pdf
WHO. Guidelines for the treatment of malaria. Geneva: World Health Organization; 2006. http://whqlibdoc.who.int/publications/2006/9241546948_eng.pdf
WHO. Assessment and monitoring of Antimalarial drug efficacy for the treatment of uncompcicated falciparum malaria. Geneva: World Health Organization; 2003. http://www.who.int/malaria/docs/ProtocolWHO.pdf
Song JP, Socheat D, Seila S, Tharith T, Satim S, Yuthease S, et al. Clinical observation of dihydroartemisinin-piperaquine phosphate in treatment of uncomplicated falciparum malaria. Natl Med J Chin (Chin) 2003;83: 1099–1100.
Karema C, Fanello CI, van Overmeir C, van Geertruyden JP, van Doren W, Ngamije D, et al. Safety and efficacy of dihydroartemisinin/piperaquine (Artekin) for the treatment of uncomplicated plasmodium falciparum malaria in Rwandan children. Trans R Soc Trop Med Hyg 2006;100:1105–1111.
Tangpukdee N, Krudsood S, Thanachartwet W, Chalermrut K, Pengruksa C, Srivilairit S, et al. An open randomized clinical trial of Artekin vs artesunate-mefloquine in the treatment of acute uncomplicated falciparum malaria. Southeast Asian J Trop Med Public Health 2005;36:1085–1091.
Song JP, Fu LC, Tan B, Li GQ. Randomized controlled trial of dihydroartemisinin piperaquine phosphate tablets in treatment of uncomplicated falciparum malaria. Chin J New Drugs (Chin) 2004;11: 783–785.
Chen L, Qu FY, Zhou YC. Field observation on the antimalarial piperaquine. Chin J Med (Chin) 1982; 95:281–286.
Tran TH, Dolecek C, Pham PM, Nguyen TD, Nguyen TT, Le HT, et al. Dihydroartemisinin-piperaquine against multidrug-resistant plasmodium falciparum malaria in Vietnam: randomised clinical trial. Lancet 2004;363:18–22.
Artemisinin as a Chinese medicine, selectively induces apoptosis in pancreatic tumor cell line
Endorsement of CONSORT by Chinese medical journals: A survey of “instruction to authors”
A randomized controlled trial of adjunctive Bunchang Naoxintong Capsule (步长脑心通胶囊) versus maintenance dose clopidogrel in patients with CYP2C19*2 polymorphism
Astragalus membranaceus Injection combined with conventional treatment for viral myocarditis: A systematic review of randomized controlled trials
Efficacy of Gastrosis No.1 compound on functional dyspepsia of spleen and stomach deficiency-cold syndrome: A multi-center, double-blind, placebo-controlled clinical trial
相关作者
暂无数据
相关机构
Department of Biochemistry, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran
Department of Immunology, School of Medical Sciences, Tarbiat Modares University, Tehran
Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine
First Hospital Affiliated to Tianjin University of Traditional Chinese Medicine
Evidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine